--- schema_version: "secwatch.filing_event.v1" accession: "0001140361-23-028261" form_type: "8-K" ticker: "IONS" cik: "0000874015" company_name: "IONIS PHARMACEUTICALS INC" filed_at: "2023-06-05T23:59:59+00:00" generated_at: "2026-06-14T07:44:16.920111+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.25 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Ionis shareholders approve director elections, equity plan amendment, and auditor ratification at annual meeting ## Summary - Four directors elected: Berthelsen, Herman, Parshall, Wender; each received >88M votes for. - Shareholders approved advisory say-on-pay (117M for) and set frequency at 1 year (119M votes). - Equity incentive plan amended to add 5.5M shares; total authorized shares increase to 35.2M. - Ratified vesting acceleration for new non-employee directors (3-year) and E&Y as auditor. - All six proposals passed as recommended by Board. ## SEC filing metadata - accession: 0001140361-23-028261 - form_type: 8-K - ticker: IONS - cik: 0000874015 - company_name: IONIS PHARMACEUTICALS INC - filed_at: 2023-06-05T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.25 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/brhc20054000_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001140361-23-028261 - JSON: https://secwatch.observer/filing/0001140361-23-028261.json - Plain text: https://secwatch.observer/filing/0001140361-23-028261.txt ## Key facts - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Election of directors to hold office until the 2026 Annual Meeting at the 2023-06-01 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 1: Election of directors to hold office until the 2026 Annual Meeting: FOR WITHHELD BROKER NON-VOTES Spencer R. Berthelsen 91,194,334 28,917,691 9,823,268 Joan E. Herman 115,174,011 4,938,014 9,823,268 B. Lynne Parshall 101,641,511 18,470,514 9,823,268 Joseph H. Wender 88,160,292 31,951,733 9,823,268 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares at the 2023-06-01 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 4 : Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares: FOR AGAINST ABSTAIN BROKER NON-VOTES 88,929,162 31,115,758 67,105 9,823,268 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s executive officers at the 2023-06-01 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 2 : Approval, on an advisory basis, of the compensation paid to the Company’s executive officers, including the following resolution: “RESOLVED, that Ionis’ stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2023 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.” FOR AGAINST ABSTAIN BROKER NON-VOTES 117,265,241 2,746,636 100,148 9,823,268 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation at the 2023-06-01 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 3 : Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation: 1 YEAR 2 YEARS 3 YEARS ABSTAIN 119,423,064 134,181 475,080 79,700 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Ratification of increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years at the 2023-06-01 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 5 : Ratification of increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years: FOR AGAINST ABSTAIN BROKER NON-VOTES 100,409,115 19,628,971 73,939 9,823,268 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year at the 2023-06-01 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-01 source text: Proposal 6: Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 127,567,008 2,276,019 92,266 0 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123028261/0001140361-23-028261-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.